Security Snapshot

IRONWOOD PHARMACEUTICALS INC - NOTE 1.500% 6/1 Institutional Ownership

CUSIP: 46333XAH1

13F Institutional Holders and Ownership History from Q3 2020 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

13

Principal

$183,087,000

Price (% of par)

98.25%

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Principal change
-$420,000
Market value change
+$4,521,837
Number of holders
13
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • 46333XAH1 - IRONWOOD PHARMACEUTICALS INC - NOTE 1.500% 6/1 is tracked under CUSIP 46333XAH1.
  • 13 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 13 to 0 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $186,419,553 to $0.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 13 institutions filings for Q1 2026.

Open SEC evidence

Security key

46333XAH1

Latest holder period

Q1 2026

13F holders

13

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 13 institutional investors reported holding $183,087,000 in principal (par value) of IRONWOOD PHARMACEUTICALS INC - NOTE 1.500% 6/1.

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
24
Latest
Q1 2026
Rows shown
1-24 of 24
Period Principal Value Change Price (% of par) (Median) Investors
2026 Q2 $0 $0 -$65,564,447 0
2026 Q1 $183,087,000 $186,419,553 +$4,521,837 98.25% 13
2025 Q4 $183,507,000 $177,678,590 +$17,140,925 94.72% 12
2025 Q3 $170,823,077 $177,255,350 -$449,580 89.5% 10
2025 Q2 $167,434,077 $168,923,031 -$617,713 84.82% 11
2025 Q1 $165,440,927 $177,805,855 -$118,626 88.89% 13
2024 Q4 $162,485,927 $181,412,896 -$5,361,158 91.88% 15
2024 Q3 $174,660,250 $155,061,380 -$26,714,854 88.54% 19
2024 Q2 $199,579,000 $188,232,680 -$1,536,486 93.95% 19
2024 Q1 $197,210,000 $200,950,767 -$4,539,819 101.32% 26
2023 Q4 $197,783,681 $214,752,759 -$57,796,947 108.35% 23
2023 Q3 $253,984,309 $234,677,877 +$47,095,659 97.69% 21
2023 Q2 $195,096,314 $199,278,621 -$3,822,597 102.09% 17
2023 Q1 $199,068,000 $199,949,244 +$3,671,564 100.21% 23
2022 Q4 $193,506,792 $212,083,816 +$3,261,653 109.47% 26
2022 Q3 $172,661,287 $175,938,133 -$19,057,125 101.75% 24
2022 Q2 $191,310,000 $206,431,392 -$3,075,326 108.0% 21
2022 Q1 $193,608,500 $227,878,494 -$1,405,092 117.86% 19
2021 Q4 $195,546,000 $222,198,820 -$9,175,256 113.74% 19
2021 Q3 $198,153,834 $243,379,250 +$25,811,035 120.74% 19
2021 Q2 $176,649,934 $211,202,719 +$8,625,093 119.71% 18
2021 Q1 $169,573,934 $191,711,949 -$4,712,158 113.2% 17
2020 Q4 $173,803,000 $196,230,527 +$1,158,829 112.6% 17
2020 Q3 $173,624,321 $169,841,000 +$169,841,000 97.63% 18
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .